Avanos Medical, Inc. (AVNS): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la tecnología médica, Avanos Medical, Inc. (AVNS) surge como una fuerza transformadora, navegando estratégicamente el complejo ecosistema de salud a través de su modelo de negocio meticulosamente elaborado. Al integrar a la perfección las soluciones innovadoras de manejo del dolor, las intervenciones quirúrgicas avanzadas y las tecnologías de dispositivos médicos de vanguardia, Avanos se ha posicionado como un jugador fundamental en la entrega de innovaciones de atención médica centradas en el paciente. Este lienzo de modelo comercial integral revela el intrincado marco estratégico que impulsa el notable éxito de AVNS, ofreciendo una visión sin precedentes de cómo la empresa crea, ofrece y captura valor en la industria de dispositivos médicos altamente competitivos.

Avanos Medical, Inc. (AVNS) - Modelo de negocios: asociaciones clave

Fabricantes de dispositivos médicos estratégicos

Avanos Medical colabora con los siguientes fabricantes de dispositivos médicos estratégicos:

Pareja	Enfoque de asociación	Año establecido
Salud cardinal	Cadena de suministro y distribución	2018
Industrias Medline	Adquisición de dispositivos médicos	2019

Distribuidores y proveedores de atención médica

Las asociaciones clave de distribución de atención médica incluyen:

• AmerisourceBergen
• McKesson Corporation
• Henry Schein Medical

Investigaciones de instituciones y universidades

Avanos Medical's Research Collaboration Partners:

Institución	Área de investigación	Valor de colaboración
Universidad de Johns Hopkins	Tecnologías de manejo del dolor	$ 2.3 millones anualmente
Escuela de Medicina de Stanford	Innovación quirúrgica	$ 1.7 millones anuales

Centros y hospitales quirúrgicos

Avanos Medical's Hospital Network Asociaciones:

• Clínica de mayonesa
• Clínica de Cleveland
• Nyu Langone Health

Socios de innovación de tecnología médica

Detalles de colaboración de innovación tecnológica:

Pareja	Enfoque de innovación	Inversión
Medtrónico	Soluciones avanzadas de manejo del dolor	Inversión de I + D de $ 5,6 millones
Boston Scientific	Tecnologías intervencionistas	Investigación colaborativa de $ 4.2 millones

Avanos Medical, Inc. (AVNS) - Modelo de negocio: actividades clave

Investigación y desarrollo de dispositivos médicos

Inversión en I + D en 2023: $ 74.2 millones

Áreas de enfoque de I + D	Porcentaje de inversión
Tecnologías de manejo del dolor	42%
Productos de intervención quirúrgica	33%
Soluciones respiratorias avanzadas	25%

Diseño de solución de manejo del dolor avanzado

Portafolio de productos de manejo total del dolor: 17 dispositivos médicos especializados

• Sistemas de intervención de dolor crónico
• Tecnologías agudas de manejo del dolor
• Bloque nervioso y soluciones de anestesia regional

Fabricación de productos quirúrgicos e intervencionistas

Capacidad de fabricación anual: 2,4 millones de dispositivos médicos

Ubicación de fabricación	Volumen de producción
Estados Unidos	1.6 millones de unidades
México	0.8 millones de unidades

Control de calidad y cumplimiento regulatorio

Certificaciones regulatorias: FDA, ISO 13485: 2016

• Frecuencia de auditoría de calidad anual: 4 veces al año
• Inversión de cumplimiento: $ 22.3 millones en 2023
• Personal de control de calidad: 126 especialistas

Marketing y ventas de productos médicos

2023 Presupuesto de marketing: $ 98.6 millones

Canal de ventas	Contribución de ingresos
Ventas directas	62%
Red de distribuidores	38%

Avanos Medical, Inc. (AVNS) - Modelo de negocio: recursos clave

Experiencia especializada en ingeniería médica

A partir de 2024, Avanos Medical emplea a aproximadamente 2,200 profesionales con antecedentes especializados de ingeniería médica. El equipo de ingeniería de la compañía posee 272 patentes activas en tecnologías de dispositivos médicos.

Instalaciones de fabricación avanzadas

Ubicación	Tamaño de la instalación	Capacidad de producción
Austin, Texas	85,000 pies cuadrados	3.2 millones de dispositivos médicos anualmente
Alpharetta, Georgia	65,000 pies cuadrados	2.7 millones de dispositivos médicos anualmente

Patentes de propiedad intelectual y dispositivos médicos

La cartera de patentes actual incluye:

• 272 Patentes activas de dispositivos médicos
• 87 Pensas de patentes pendientes
• Valoración de patentes estimada en $ 124 millones

Equipo de investigación y desarrollo

Inversión de I + D en 2023: $ 87.3 millones, que representa el 6.4% de los ingresos totales de la compañía.

Infraestructura de tecnología médica

Inversiones de infraestructura tecnológica:

• Infraestructura de computación en la nube: $ 12.4 millones
• Sistemas avanzados de imágenes médicas: $ 9.7 millones
• AI y plataformas de investigación de aprendizaje automático: $ 6.2 millones

Avanos Medical, Inc. (AVNS) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de dispositivos médicos

Avanos Medical, Inc. reportó ingresos totales de $ 812.4 millones para el año fiscal 2022. Las innovadoras soluciones de dispositivos médicos de la compañía se centran en líneas de productos especializadas en múltiples segmentos de atención médica.

Categoría de productos	Contribución de ingresos	Segmento de mercado
Dispositivos quirúrgicos	$ 342.6 millones	Soluciones de sala de operaciones
Tecnologías de manejo del dolor	$ 270.8 millones	Manejo del dolor intervencionista
Productos de atención respiratoria	$ 199 millones	Atención hospitalaria y doméstica

Tecnologías avanzadas de manejo del dolor

Avanos Medical se especializa en tecnologías de manejo del dolor con un enfoque en soluciones de intervención.

• Coolief* Tratamiento de radiofrecuencia enfriada: penetración del mercado del 17% en el segmento de manejo del dolor crónico
• Sistemas de catéter de bloqueo nervioso avanzado con una calificación de efectividad clínica del 92%
• Portafolio de gestión del dolor patentado que genera $ 270.8 millones en ingresos anuales

Productos de intervención quirúrgica de alta calidad

La línea de productos de intervención quirúrgica genera ingresos significativos con tecnologías médicas precisas.

Línea de productos quirúrgicos	Cuota de mercado	Ingresos anuales
Dispositivos de cierre de heridas quirúrgicas	12.5%	$ 156.3 millones
Sistemas de drenaje quirúrgico	8.7%	$ 112.4 millones

Innovaciones de atención médica centradas en el paciente

Avanos Medical invirtió $ 64.2 millones en investigación y desarrollo durante 2022, centrándose en soluciones médicas centradas en el paciente.

• 3 nuevas patentes presentadas en tecnologías de monitoreo de pacientes
• Tasa de éxito del ensayo clínico del 76% para nuevos dispositivos médicos
• Calificación de satisfacción del paciente del 94% en las líneas de productos

Diseño de equipos médicos de precisión

Enfoque de diseño de precisión respaldado por sustanciales inversiones de investigación.

Inversión de diseño	Tamaño del equipo de ingeniería	Ciclo de desarrollo de productos
Presupuesto de I + D de $ 64.2 millones	387 profesionales de ingeniería	18-24 meses por producto

Avanos Medical, Inc. (AVNS) - Modelo de negocios: relaciones con los clientes

Equipos directos de soporte de ventas

Avanos Medical mantiene 127 representantes de ventas directas a partir del cuarto trimestre de 2023, que cubre las instalaciones de salud en todo Estados Unidos. Compensación promedio de representantes de ventas anuales: $ 185,700.

Métrica del equipo de ventas	2023 datos
Representantes de ventas totales	127
Compensación anual promedio	$185,700
Cobertura geográfica	Estados Unidos

Consulta de productos médicos técnicos

Tamaño del equipo de consulta técnica: 42 expertos en productos médicos especializados. Tiempo de respuesta promedio para consultas técnicas: 2.4 horas.

• Disponibilidad de soporte técnico 24/7
• Servicios de consulta multilingüe
• Duración promedio de consulta de expertos: 47 minutos

Plataformas de servicio al cliente en línea

Los canales de servicio al cliente digital incluyen:

• Portal web con 99.7% de tiempo de actividad
• Descargas de aplicaciones móviles: 42,500 en 2023
• Tiempo promedio de resolución de interacción digital: 3.2 horas

Programas de capacitación profesional médico

Métrica del programa de capacitación	2023 datos
Sesiones de entrenamiento totales	218
Participantes entrenados	3,642
Duración promedio de entrenamiento	6.5 horas

Soporte de dispositivos médicos personalizados

Métricas de apoyo personalizadas:

• Gerentes de cuentas dedicados: 87
• Calificación de satisfacción del cliente: 94.3%
• Tiempo promedio de personalización del dispositivo: 5.6 días

Avanos Medical, Inc. (AVNS) - Modelo de negocios: canales

Fuerza de ventas directa

A partir de 2024, Avanos Medical mantiene un equipo de ventas interno dedicado de aproximadamente 287 representantes de ventas directas centrados en mercados quirúrgicos e intervencionistas.

Categoría de canal de ventas	Número de representantes	Segmento del mercado objetivo
Equipo de ventas quirúrgicas	162	Hospitales y centros quirúrgicos
Equipo de ventas intervencionistas	125	Clínicas médicas especializadas

Redes de distribuidores de dispositivos médicos

Avanos Medical se asocia con 73 distribuidores de dispositivos médicos nacionales e internacionales en 12 países.

• Red de distribución norteamericana: 42 distribuidores
• Red de distribución europea: 19 distribuidores
• Red de distribución de Asia-Pacífico: 12 distribuidores

Plataformas de comercio electrónico en línea

Los canales de ventas digitales generan $ 47.3 millones en ingresos anuales para Avanos Medical en 2024.

Plataforma de comercio electrónico	Volumen de ventas anual	Porcentaje de ingresos digitales
Sitio web de la compañía directa	$ 22.6 millones	47.8%
Mercados médicos de terceros	$ 24.7 millones	52.2%

Exposiciones de conferencia médica

Avanos Medical participa en 37 conferencias médicas anualmente, con una inversión de exhibición estimada de $ 2.1 millones.

Marketing digital profesional de la salud

Presupuesto de marketing digital asignado: $ 6.5 millones en 2024, dirigido a profesionales de la salud en múltiples canales digitales.

Canal de marketing digital	Presupuesto asignado	Público objetivo
Publicidad profesional de LinkedIn	$ 2.3 millones	Médicos y administradores de atención médica
Plataformas web médicas especializadas	$ 1.8 millones	Especialistas médicos
Publicidad digital programática	$ 2.4 millones	Segmento de profesional de atención médica amplia

Avanos Medical, Inc. (AVNS) - Modelo de negocios: segmentos de clientes

Hospitales y centros quirúrgicos

A partir de 2023, Avanos Medical atiende a aproximadamente 5.600 hospitales en los Estados Unidos. La penetración del mercado de la compañía incluye:

Tipo de hospital	Número de instalaciones	Penetración del mercado
Grandes centros médicos académicos	287	82%
Hospitales comunitarios	4,813	65%
Hospitales quirúrgicos especializados	500	73%

Anestesiólogos y especialistas en manejo del dolor

Avanos Medical apunta a aproximadamente 52,000 anestesiólogos en ejercicio en los Estados Unidos.

• Valor del segmento del mercado de manejo del dolor: $ 71.3 mil millones en 2023
• Base de clientes especializados específicos: 18,500 profesionales del manejo del dolor
• Poder de compra de productos anual por especialista: $ 157,000

Médicos intervencionistas

Desglose del segmento de clientes para especialistas intervencionistas:

Especialidad	Número de practicantes	Gasto anual promedio de productos
Radiólogos intervencionistas	6,200	$94,500
Cardiólogos intervencionistas	8,700	$112,300

Departamentos de adquisición de atención médica

El segmento de clientes de adquisición de Avanos Medical incluye:

• Organizaciones de compras grupales (GPO): 8 principales redes nacionales
• Departamentos totales de adquisición atendidos: 3.200
• Valor anual del contrato: $ 42.6 millones

Centros quirúrgicos ambulatorios

Detalles del segmento de mercado para centros quirúrgicos ambulatorios:

Tipo central	Centros totales	Penetración del mercado de Avanos	Contribución anual de ingresos
ASC ortopédicos	4,100	57%	$ 23.4 millones
ASC de especialidad	5,600	49%	$ 18.7 millones

Avanos Medical, Inc. (AVNS) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2022, Avanos Medical, Inc. invirtió $ 40.5 millones en gastos de investigación y desarrollo, lo que representa el 6.1% de los ingresos totales.

Año	Inversión de I + D	Porcentaje de ingresos
2022	$ 40.5 millones	6.1%
2021	$ 38.2 millones	5.8%

Gastos de fabricación y producción

Los costos totales de fabricación para Avanos Medical en 2022 fueron de aproximadamente $ 261.7 millones, lo que incluye mano de obra directa, materiales y gastos generales.

• Costos de material directo: $ 142.3 millones
• Costos laborales directos: $ 63.5 millones
• Sobrecoss de fabricación: $ 55.9 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para Avanos Medical en 2022 totalizaron $ 146.3 millones, lo que representa el 22% de los ingresos totales.

Categoría de gastos	Cantidad
Costos del personal de ventas	$ 82.7 millones
Campañas de marketing	$ 38.5 millones
Infraestructura de soporte de ventas	$ 25.1 millones

Costos de cumplimiento regulatorio

Los gastos de cumplimiento regulatorio para Avanos Medical en 2022 fueron de $ 23.6 millones, lo que incluye actividades de garantía de calidad, certificación y cumplimiento legal.

Mantenimiento de la infraestructura tecnológica

Los costos de mantenimiento de la tecnología y la infraestructura de TI para 2022 ascendieron a $ 32.4 millones, cubriendo software, hardware, ciberseguridad e inversiones de infraestructura digital.

Categoría de costos tecnológicos	Cantidad
Licencia de software	$ 12.6 millones
Infraestructura de hardware	$ 9.8 millones
Inversiones de ciberseguridad	$ 6.5 millones
Iniciativas de transformación digital	$ 3.5 millones

Avanos Medical, Inc. (AVNS) - Modelo de negocios: flujos de ingresos

Venta de productos de dispositivos médicos

Año fiscal 2022 Ingresos totales: $ 806.4 millones

Categoría de productos	Ingresos ($ M)	Porcentaje
Manejo del dolor crónico	$380.2	47.1%
Manejo del dolor intervencionista	$276.5	34.3%
Productos quirúrgicos	$149.7	18.6%

Ingresos de equipos de intervención quirúrgica

2022 Ingresos del equipo quirúrgico: $ 149.7 millones

• Productos de drenaje quirúrgico especializado
• Soluciones de gestión de heridas quirúrgicas
• Tecnologías avanzadas de intervención quirúrgica

Licencias de solución de manejo del dolor

Ingresos de licencia para 2022: $ 42.3 millones

Categoría de licencias	Ingresos ($ M)
Tecnología de dolor crónico	$28.6
Soluciones de dolor intervencionista	$13.7

Contratos de servicio de tecnología médica

Ingresos del contrato de servicio para 2022: $ 33.5 millones

• Mantenimiento del dispositivo médico
• Acuerdos de soporte técnico
• Servicios de instalación y capacitación

Tarifas recurrentes de mantenimiento de productos

Ingresos de tarifas de mantenimiento para 2022: $ 22.9 millones

Tipo de mantenimiento	Ingresos ($ M)
Dispositivos de dolor crónico	$14.6
Mantenimiento de equipos quirúrgicos	$8.3

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Avanos Medical, Inc. (AVNS) products, grounded in their late 2025 performance data. The value propositions center on clinical differentiation and strategic portfolio focus.

Opioid-sparing, non-invasive chronic pain relief (RFA)

Avanos Medical, Inc. offers Radiofrequency Ablation (RFA) solutions as a key component in addressing the need for alternatives to systemic opioids for pain management. The momentum in this area is clear from recent results.

• Net sales of RFA products grew by 10.5% in the third quarter of 2025.
• The overall Pain Management & Recovery (PM&R) segment net sales for Q3 2025 were $59.0 million, an increase of $1.2 million versus the prior year period.
• This growth reflects sustained momentum in RFA generator sales, which directly resulted in higher procedural volumes across their product lines.

Life-sustaining enteral feeding and neonatal solutions

The Specialty Nutrition Systems (SNS) segment provides vital support for patients requiring long-term nutrition, including neonates. This segment is a primary growth engine for Avanos Medical, Inc.

• SNS achieved 14.5% organic growth in the third quarter of 2025.
• For the first nine months of 2025, SNS net sales reached $317.8 million, representing an increase of $27.3 million compared to the prior year period, driven by 9.1% volume growth.
• The NeoMed product offering, part of the neonatal solutions, exceeded $100 million of annualized revenue as of December 2024, maintaining the number one share position in the US.
• Operating income for the SNS segment for the first nine months of 2025 was $62.1 million, which is 19.5% of SNS net sales.

Safer, more consistent nutrition/medication delivery

Avanos Medical, Inc. focuses on improving the reliability and safety of feeding delivery, particularly through standardization and technology adoption.

The value here is tied to preventing adverse events and ensuring proper nutrient uptake, supported by specific product adoption metrics.

• Short-term feeding portfolio growth is driven by the continued expansion of their US CORTRAK standard of care offerings.
• The shift to new alternatives like the ENFit connectors helps prevent hospital-never events, a critical safety metric in feeding.
• Reimbursement for long-term feeding patients in the US is described as robust and not expected to change soon.

Clinically superior, evidence-based medical devices

The company emphasizes that its devices offer superior clinical outcomes, which drives adoption, especially in the enteral feeding space where CORTRAK is mentioned as a standard of care offering.

Here's a quick look at the segment performance that underpins the overall financial health, which supports continued R&D and market presence:

Metric (As of 9M 2025)	Value	Segment
Total Net Sales	$520.3 million	Company-wide
Total Net Sales Growth (vs prior year)	2.4%	Company-wide
Adjusted Gross Margin (Q3 2025)	52.8%	Company-wide
RFA Product Net Sales Growth (Q3 2025)	10.5%	PM&R
SNS Segment Operating Profit Margin (9M 2025)	19.5%	SNS

Focus on high-growth, core segments for investors

Avanos Medical, Inc. is actively refining its portfolio to concentrate capital and resources on areas with the highest growth potential, signaling a clear strategic direction for investors.

This focus is evidenced by recent portfolio management actions:

• The company announced the divestiture of its Hyaluronic Acid (HA) business on July 31, 2025.
• They are executing an exit from the IV infusion products category, planned for early 2026.
• The acquisition of Nexus Medical is expected to be immediately accretive and provides access to a $70 million market segment.
• Management has initiated a $15 million-$20 million cost savings initiative.
• The full-year 2025 revenue estimate was raised to a range of $690 million to $700 million, with the adjusted EPS estimate raised to $0.85 to $0.95 per share.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Relationships

You're looking at how Avanos Medical, Inc. (AVNS) builds and maintains its ties with the people and institutions that buy its products. This isn't just about transactions; it's about deep integration, especially in specialized areas like pain management and nutrition.

Dedicated clinical training and support for RFA procedures

Avanos Medical, Inc. supports its Radiofrequency Ablation (RFA) solutions with a history of clinical engagement. The company notes having over 20 years of experience working with leading institutions to develop successful pain management programs. The focus here is on ensuring providers can use the technology effectively, which is critical for procedures where patient outcomes are paramount. For instance, the momentum in RFA generator sales, which drove RFA product net sales growth of 10.9% for the nine months ended September 30, 2025, relies on this support structure.

The relationship is reinforced through educational efforts, such as hosting industry symposiums like the one at ASRA 2025, focusing on opioid-sparing therapies.

Long-term contracts with major hospital systems/IDNs

While specific contract values aren't public, the relationship strategy involves deep integration within hospital systems. The growth in the Pain Management & Recovery (PM&R) segment, which saw net sales of $176.2 million for the nine months ended September 30, 2025, reflects ongoing engagement with these facilities. The company's portfolio, including RFA products, is positioned to support hospital operations by offering evidence-based, non-narcotic solutions for chronic pain management, which is a key concern for hospital administrators focused on efficiency and reputation.

Direct-to-patient support for chronic care products

For its Specialty Nutrition Systems (SNS) segment, which provides a lifeline for nutrition from hospital to home, Avanos Medical, Inc. is taking steps to enhance direct control over the customer experience. A concrete action in this area is the expansion of direct operations for MIC-KEY enteral feeding products into the United Kingdom, effective July 2025. This move signals a commitment to a more direct relationship with the end-user base for chronic care. The SNS segment showed strong performance, with net sales of $317.8 million and 9.1% volume growth for the first nine months of 2025.

High-touch, consultative sales for capital equipment

The sales approach for capital equipment, like RFA generators, is consultative, focusing on providing a full suite of options-cooled, 3-tined, and conventional RFA-to tailor treatment plans. This consultative model supports the sales momentum seen in the PM&R segment. The company has a dedicated sales force and customer support team with significant industry experience and product training supporting its franchises.

Digital tools for product reordering and education

Avanos Medical, Inc. is focused on operational optimization, which includes digital components, though specific usage metrics for reordering aren't detailed. The company's overall transformation priorities through 2025 included strategic and commercial optimization. The company employs more than 2,200 people worldwide, supporting its global footprint and product marketing efforts. The overall net sales for the last twelve months ending September 30, 2025, reached $699.90 million.

Here's a quick look at the scale of the business supporting these relationships as of late 2025:

Metric	Value (Latest Reported Period)
Total Net Sales (Last Twelve Months ending Q3 2025)	$699.90 million
SNS Segment Net Sales (9 Months ended Sep 30, 2025)	$317.8 million
PM&R Segment Net Sales (9 Months ended Sep 30, 2025)	$176.2 million
RFA Product Net Sales Growth (9 Months ended Sep 30, 2025)	10.9%
Total Employees Worldwide (As of 2024)	More than 2,200

The company's 2025 estimated revenue guidance was set between $665 million and $685 million.

The relationship strategy is supported by a structure that includes:

• A dedicated sales force for each franchise.
• Customer support teams with significant industry experience.
• A medical education program with HCP-led training.
• Local, in-person support and training availability.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Channels

You're looking at how Avanos Medical, Inc. gets its clinically superior medical device solutions into the hands of healthcare providers and patients as of late 2025. The channel strategy is clearly evolving, moving toward more direct control where it makes strategic sense, while still relying on established networks for broad reach.

Here's a quick look at the top-line financial context for the channels to consider:

Metric	Value (as of late 2025)	Period/Date
Trailing 12-Month Revenue	$700 Million USD	As of September 30, 2025
Full-Year 2025 Net Sales Guidance (Raised)	$690 Million to $700 Million	Updated Guidance
Q3 2025 Enteral Feeding Unit Revenue	$82.7 Million	Q3 2025
Q3 2025 Neonate Solutions Unit Revenue	$31.3 Million	Q3 2025

The company develops, manufactures, and markets its recognized brands globally, holding leading market positions in multiple product categories across its portfolio.

Direct sales force to hospitals and ASCs

Avanos Medical, Inc. markets its products generally directly to hospitals and other healthcare providers. This direct engagement is crucial for complex devices and capital equipment sales, especially within the Pain Management & Recovery (PM&R) segment, which includes Radiofrequency Ablation (RFA) generator sales that grew 10.5% year over year in Q3 2025 to $34.6 million. The direct sales effort supports the company's commitment to reducing opioid use and helping patients move from surgery to recovery.

Third-party medical device distributors globally

While pushing for direct relationships, a significant portion of sales still flows through third-party wholesale distributors. For the year ended December 31, 2024, approximately 50% of North America net sales were executed via these distributors. Two major distributors, McKesson Corporation and Medline Industries, accounted for approximately 18% and 17% of consolidated net sales in 2024, respectively. Globally, the MIC-KEY product line, which is part of the Specialty Nutrition Systems (SNS) segment, is sold in over 60 countries across six continents.

Direct-to-home patient supply for chronic care

A key part of the Avanos Medical mission involves providing a vital lifeline for nutrition to patients from hospital to home. This is primarily served through the Chronic Care franchise, now integrated into the Digestive Health focus within the combined commercial organization. The Enteral feeding unit, which supports this continuum of care, generated net sales of $82.7 million in the third quarter of 2025, representing a 14.9% increase year over year.

Strategic transition to direct operations (e.g., UK MIC-KEY)

Avanos Medical, Inc. is actively strengthening its direct control over key product lines. A major example is the strategic transition for the MIC-KEY enteral feeding products in the United Kingdom. Effective July 25, 2025, Avanos took direct responsibility for sales and distribution, ending a 29-year distribution partnership with Vygon UK. This move is intended to enhance customer relationships and improve service efficiency by eliminating the intermediary.

E-commerce and online portals for consumables

The company is focused on go-to-market strategies to accelerate growth, which includes enhancing customer engagement. The channels used for consumables, which are typically lower-touch items supporting the core devices, are increasingly being managed through digital means. The company plans to guide healthcare facilities through new ordering processes following the UK transition to ensure continuity.

• The company is focused on advancing its strategic segments in PM&R and SNS following the July 2025 divestiture of its Hyaluronic Acid (HA) product line.
• The SNS segment saw volume growth of 14% in Q3 2025, driven by long-term feeding products.
• The company's overall strategy involves commercial optimization and supply chain effectiveness.
• The direct control in the UK aims to ensure uninterrupted access to MIC-KEY products.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Segments

Hospitals and Integrated Delivery Networks (IDNs)

• SNS segment net sales for the third quarter of 2025 totaled $114.0 million.
• PM&R segment net sales for the third quarter of 2025 totaled $59 million.
• The Specialty Nutrition Systems (SNS) segment recorded volume growth of 14.0% in the third quarter of 2025.
• The full-year 2025 revenue guidance is between $690 million and $700 million.

Pain management specialists and anesthesiologists

Pain Management Sub-Segment	Q3 2025 Net Sales (in millions)	Year-over-Year Change
Radiofrequency Ablation (RFA) products	$34.60 million	Up 10.5%
Surgical pain and recovery	$24.40 million	Down 7.9%

Neonatal and Pediatric Intensive Care Units (NICUs/PICUs)

• Neonate solutions unit revenue for the third quarter of 2025 amounted to $31.3 million.
• Neonate solutions revenue growth year-over-year for the third quarter of 2025 was 19.5%.
• Avanos Medical, Inc. completed the acquisition of Nexus Medical, which is expected to deliver immediate value in NICU and PICU care.

Patients requiring long-term enteral feeding

• Enteral feeding unit revenue for the third quarter of 2025 totaled $82.70 million.
• Enteral feeding revenue growth year-over-year for the third quarter of 2025 was 14.9%.
• The company noted strong demand for its long-term feeding products in the third quarter of 2025.

Ambulatory Surgery Centers (ASCs) for RFA procedures

• RFA product net sales grew 10.5% year-over-year in the third quarter of 2025.
• RFA capital equipment sales drove procedural volumes in the third quarter of 2025.
• The Radiofrequency Ablation (RFA) business posted double-digit growth in the third quarter of 2025 compared to the previous year.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Avanos Medical, Inc. (AVNS) engine as of late 2025. It's a mix of necessary investment for growth, the lingering effects of external pressures, and costs tied to strategic restructuring. Honestly, keeping the lights on and investing for the future requires significant outlay across the board.

High Cost of Goods Sold (COGS) due to tariff headwinds

Tariffs are definitely biting into the gross margin. For the second quarter of 2025, the reported gross profit margin was 52.6%, a notable drop from 55.7% in the prior year period. Management specifically cited higher tariffs as a primary driver for this contraction, alongside lower pricing on the Hyaluronic Acid (HA) products before that line was divested. Looking ahead, the full-year 2025 free cash flow forecast is explicitly inclusive of an estimated $18 million tariff impact. The company is actively working on mitigation, including supply-chain relocation and a plan to exit China for neonatal syringe production by mid-2026, which is driving higher capital expenditures in 2025.

Significant R&D and SG&A investment for core growth

Investing in the core segments-Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R)-means keeping R&D and SG&A spending at meaningful levels. You see the discipline in the latest quarterly figures, but the absolute spend is still substantial. Here's a snapshot of the most recent reported operating expenses from the third quarter of 2025:

Expense Category	Q3 2025 Amount	Year-over-Year Change	Context/Metric
Selling and General Expenses	$83.5 million	Increased 3.2%	Reported for the quarter
Research and Development Expenses	$5.8 million	Decreased 7.9%	Reported for the quarter
Adjusted SG&A as % of Revenue	40.6%	N/A	Q3 2025 metric
SG&A as % of Net Sales (Full Year 2024)	46.3%	Decreased from 49.8%	Driven by transformation and divestiture costs

The company is streamlining management and revamping R&D with a hybrid model to accelerate product development, aiming for $15 million to $20 million in run-rate annualized cost savings by 2026.

Transformation costs, including $10 million one-time Q4 2025 charges

The ongoing transformation process, initiated in January 2023, carries specific one-time costs. Management anticipates approximately $10 million in one-time cash charges related to expanded cost programs, with the majority expected to be incurred in 2025. This $10 million in transformation-related charges is explicitly factored into the full-year 2025 free cash flow forecast of $25 million-$30 million.

Manufacturing and supply chain expenses

While specific manufacturing cost line items aren't broken out separately from COGS, supply chain expenses are embedded within the margin pressures and capital expenditure plans. The company is focused on improving profitability in certain areas, such as transitioning the Game Ready U.S. Rental segment to a distribution arrangement with WRS Group. Furthermore, capital expenditures are higher in 2025 to support the planned exit from China for neonatal syringe production by mid-2026.

Amortization of acquired intangibles (e.g., Nexus Medical)

Amortization of intangible assets, stemming from prior business acquisitions, is a consistent non-cash cost. The most recent reported figure for this expense in the second quarter of 2025 was $3.0 million on an adjusted, non-GAAP basis. For comparison, the full-year 2024 amortization was $25.2 million. The recent acquisition of Nexus Medical is expected to be immediately accretive to revenue and earnings per share, meaning its related amortization will be a new component of the cost structure moving forward.

You should track the quarterly non-GAAP intangibles amortization:

• Q2 2025: $3.0 million
• Q1 2025: $2.9 million
• Full Year 2024: $25.2 million

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Avanos Medical, Inc. brings in money as of late 2025, which is heavily influenced by their recent strategic moves and acquisitions.

The company has officially raised and narrowed its full-year 2025 revenue guidance following the third quarter results.

Revenue Component	Latest Reported Period Data (Q3 2025)	FY 2025 Guidance/Estimate
Total Net Sales (FY 2025 Estimate)	$177.8 million (Q3 Actual)	$690 million to $700 million
Specialty Nutrition Systems (SNS) Net Sales	$114 million	Part of Total Guidance
Pain Management & Recovery (PM&R) Net Sales	$59 million	Part of Total Guidance
Radiofrequency Ablation (RFA) Product Sales	$34.6 million (Q3 Actual)	Q2 2025 Growth: 13.7%
Nexus Medical Acquisition Accretion	N/A (Acquisition closed 9/15)	Roughly $5 million in 2025

Sales of Specialty Nutrition Systems (SNS) products remain a primary driver, showing strong momentum.

• SNS segment recorded net sales of $114 million in the third quarter of 2025.
• This reflected 14% volume growth in the third quarter.
• The segment saw double-digit growth, anchored by enteral feeding and neonate solutions.

Revenue from Pain Management & Recovery (PM&R) devices and consumables is also critical, though it includes a mixed performance across its sub-categories.

The Radiofrequency Ablation (RFA) business within PM&R is a key growth area for device sales.

• Net sales of RFA products grew 10.5% year-over-year in Q3 2025, reaching $34.6 million.
• This follows a reported 13.7% growth rate for RFA product sales in the second quarter of 2025.
• The segment's overall growth was partially offset by a year-over-year decline of 7.9% in surgical pain and recovery unit sales.

Furthermore, the recent strategic move to acquire Nexus Medical is expected to contribute directly to the top line.

Revenue accretion from the Nexus Medical acquisition is factored into the full-year estimate, expected to contribute roughly $5 million to the 2025 total revenue figure. Finance: review the Q4 forecast to ensure the $5 million accretion is fully captured within the $690-$700 million range by Friday.